Search PubMed⌕ Search

Biomedical subjects

F Bardessono

Publications and source records attributed to F Bardessono.

5 recordsLinked to original sources
PubMed1986

Combination chemotherapy for non small cell lung cancer stage III M0-1 with cisplatin and vinblastine in a divided-dose schedule.

Twenty-nine patients with advanced non small cell lung cancer (NSCLC) were treated with a combination of high-dose cisplatin and divided-dose vinblastine. In 27 evaluable patients 15% reached partial response and 59% stable disease. Extension of disease, histological type, performance status and weight loss had no relationship to response. Median duration of response was 10.2 months with a median survival time of 15.4 months in responding patients compared with 14 months of stable disease (p:n.s.) and 4.8 months of progressive disease (p less than 0.001). Gastrointestinal, neurological side effects and the development of a severe debilitation syndrome were the most troublesome toxicities of this treatment. The regimen is not generally suitable for treatment of advanced NSCLC.

Adult↗
PubMed1985

Unresectable non-small cell lung cancer chemotherapy with high-dose cisplatin and etoposide.

69 patients with unresectable non-small cell lung cancer, previously untreated, received cisplatin 100 mg/m2 on day 1 and etoposide 120 mg/m2 on days 4, 6, 8 at 4-week intervals. 66 patients were evaluable for tumor response and toxicity. Overall objective response was 25.7% (3 complete responses and 14 partial responses). Response rate in limited disease was 41% and in patients with performance score 0 it was 40%. Squamous cell carcinoma and adenocarcinoma responded in 31 and 24% of evaluable patients. Complete response was associated with a long duration of remission. Median survival time of responding patients was significantly superior to the median of nonresponding patients (p less than 0.001) but compared to stable disease no statistical significance was demonstrable (p greater than 0.05). Hematological and renal toxicity of proposed regimen was generally mild. Nausea and vomiting were the most noxious side effects.

Aged↗
PubMedDate not supplied

[Phenomenon of primary resistance of Koch's bacillus: report on cases assembled at the pneumological hospital S. Luigi in Turin from 1972 to 1975].

In this work the authors stress the importance reached in recent years by the primary resistance phenomenon in pulmonary consumption, and they explain the results pointed out by the examination of 171 antibiograms effected from 1972 to 1975 on patients with pathological forms ascertained for the first time. They conclude by underlining the reduction of the primary resistance when employing common antibiotics and, on the contrary, its rise with the use of the rifampicin which has recently been introduced in therapy; lastly they put into evidence the epidemiological importance of the phenomenon itself.

Antitubercular Agents↗